Signal active
Investment Firm
Overview
Lonza Group AG, a Life Sciences driven chemical company, supplies active ingredients, chemical intermediates and biotechnology solutions to the pharmaceutical and agrochemical industries. The company also offers a catalogue of organic intermediates for a range of applications, such as pharmaceuticals, agrochemicals, vitamins, food and feedstuff, dyes and pigments, adhesives and fragrances. It also manufactures specialty biocides and oleochemicals; and develops and produces specific polymer intermediates, unsaturated polyester-resins, compounds and composites. The company operates in three divisions that include Exclusive Synthesis & Biopharmaceuticals; Organic Fine & Performance Chemicals; and Polymer Intermediates. Exclusive Synthesis & Biopharmaceuticals In the area of Exclusive Synthesis and Biopharmaceuticals, Lonza is the custom manufacturing for the global life sciences companies. In addition to Lonza's traditional chemical custom manufacturing, Lonza offers microbial custom fermentation and biotransformation services. Lonza Biologics is focused on the production of therapeutic monoclonal antibodies and recombinant proteins produced by mammalian cell cultures. Exclusive chemical synthesis: Exclusive chemical synthesis engages in the process development and manufacture of intermediates and active ingredients. It is used in Life sciences industry, pharmaceuticals and animal health products. Exclusive microbial fermentation and biotransformation: Exclusive microbial fermentation and biotransformation processes development and manufactures intermediates, active ingredients and biopharmaceuticals. Its products are used Life sciences industry, pharmaceuticals and cosmetics. The company also offers L-Carnitine (L-Carnipure), which is applicable in sports nutrition, food, pharmaceuticals and feedstuffs. Exclusive microbial biopharma fermentation: Exclusive microbial biopharma fermentation engages in the process development and manufacture of therapeutic recombinant proteins and antibody fragments. It is used in pharmaceutical and biotechnology industry. Exclusive mammalian cell fermentation: Exclusive mammalian cell fermentation engages in the process development and manufacture of therapeutic monoclonal antibodies and recombinant proteins, proprietary GS-expression system, which are used in the pharmaceutical and biotechnology industry. Organic Fine & Performance Chemicals In the area of organic fine and performance chemicals, the company develops, manufactures, and sells various organic chemical intermediates applied in pharmaceuticals, agrochemicals, vitamins, food and feed, dyes, pigments, adhesives, and fragrances, as well as polymers. The sector performance chemical is mainly engaged in the development and production of biocides and oleochemicals. These core activities are supplemented by the polymer intermediates business, including additives, unsaturated polyester resins, compounds, and composites. Organic Fine Chemicals: The company offers Niacin, niacinamide, Diketene derivatives, Hydrocyanic acid derivatives, Engineering polymer additives and Meta – Metaldehyde. Its products are used in food and feedstuffs, pharmaceuticals, agrochemicals, colorants Vitamins, optical brighteners, agrochemicals, electronics, aerospace industry, and coating Snail. Performance Chemicals: The company offers microbiologically active substances, such as Quaternary ammonium, compounds, Halogenated hydantoins; and Hydantoin derivatives. It also offers Oleochemical derivatives. The company's products are used by the disinfectants for household, industrial and institutional applications, including water treatment and wood preservation; biocides for water treatment, pools and spas, and household disinfection; preservatives for personal care and household products; and food ingredients, humectants and emollients for personal care, processing aids and lubricants for polymer and textile industry, and industrial defoamers.
Highlights
1897
Biotechnology
10001+
7
2
1
Early Stage Venture
N/A
Location
Basel, Basel-Stadt, Switzerland, Europe
Contact Information
Social
Profile Resume
Lonza, established in 1897 and headquartered in Switzerland, Europe., specializes in Early Stage Venture investments across Biotechnology, Health Care, Pharmaceutical, Biopharma, Financial Services, Venture Capital, Life Science, Finance, Service Industry, Consumer Electronics. The organization boasts a portfolio of 7 investments, with an average round size of $46.0M and 1 successful exits. Their recent investments include Odyssey Thera, HBM Partners, Burrill & Company, ConnectedYard (pHin), Playground Global. The highest investment round they participated in was $38.0B. Among their most notable exits are Odyssey Thera and HBM Partners. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
7
0
2
1
Investments
7
Annouced Date | Organization Name | Industry | Money Raised |
---|---|---|---|
May 16, 2017 | Exosomics Siena | Health Care | null |
Mar 31, 2020 | Affinia Therapeutics | Biotechnology | 60.0M |
May 03, 2021 | Affinia Therapeutics | Biotechnology | 110.0M |
Feb 10, 2022 | Indapta Therapeutics | Biotechnology | 50.0M |
Exits
1
Funding Timeline
7
0
0
Funding Rounds
7
Lonza has raised 7 rounds. Their latest funding was raised on Feb 10, 2022 from a Series A - Indapta Therapeutics round.
Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
---|---|---|---|---|
May 16, 2017 | Funding Round - Exosomics Siena | - | 0 | - |
Mar 31, 2020 | Series A - Affinia Therapeutics | - | 60.0M | - |
May 03, 2021 | Series B - Affinia Therapeutics | - | 110.0M | - |
Feb 10, 2022 | Series A - Indapta Therapeutics | - | 50.0M | - |
Investors
1
Investor Name | Lead Investor | Funding Round | Money Raised |
---|---|---|---|
- | No | Post-IPO Debt - Lonza | 444.8M |
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
Annouced Date | Fund Name | Money Raised |
---|---|---|
May 10, 2013 | OTPPLESS | 1.0M |
May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
News
Sep 05, 2024
GEN - Genetic Engineering and Biotechnology News - Lonza Completes Expansion of Microbial Manufacturing Facility
News
Aug 28, 2024
PharmiWeb.com - Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds
News
Jul 25, 2024
MarketScreener - Lonza Shares Rise After Company Backs Outlook
News
Jul 25, 2024
PharmiWeb.com - Lonza Nominates Juan Andres and Eric Drapé as Independent Board Members
News
Jul 25, 2024
PharmiWeb.com - Lonza Group H1 2024 Performance Well On Track to Deliver...
News
Jul 24, 2024
Morningstar - Lonza Backs View Despite Earnings Slip